Dogwood Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Dogwood Therapeutics Inc (DWTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Dogwood Therapeutics Inc vs Its Competitors
- Scale: Dogwood Therapeutics Inc ranks #336 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Dogwood Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Dogwood Therapeutics inc | - | - | - | Yes |
| Competitors combined (1) | - | |||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DWTX Stock Performance relative to its Competitors
DWTX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | X4 Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Dogwood Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Dogwood Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Dogwood Therapeutics inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Dogwood Therapeutics inc | 46.42 | - |
| X4 Pharmaceuticals Inc | 380.93 | 9.44 |
| SUBTOTAL | 427.34 | 9.44 |
Sources: Dogwood Therapeutics inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Dogwood Therapeutics inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Dogwood Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Pharmagesic (Holdings) | Named by the company | 85% |
| Sealbond Limited | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Dogwood Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Dogwood Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| X4 Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Dogwood Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Dogwood Therapeutics inc | 46 | - | -4,505,161 |
| X4 Pharmaceuticals Inc | 381 | 209,800 | -2,003,067 |
| PEERS TOTAL | 381 | 209,800 | -2,003,067 |
Dogwood Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Dogwood Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Dogwood Therapeutics Inc ranks #336 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 823, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,838 | 19.26 % |
| 2 | Johnson and Johnson | 663,585 | 12.07 % |
| 3 | Beone Medicines Ltd | 552,468 | 10.05 % |
| 4 | Abbvie Inc | 471,582 | 8.58 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 336 | Dogwood Therapeutics inc | 46 | 0.00 % |
Market cap and industry share for the rest of Dogwood Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Dogwood Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 331 | Rein Therapeutics Inc | 48 | -38.91 % |
| 332 | Redhill Biopharma Ltd | 48 | -70.41 % |
| 333 | Gossamer Bio Inc | 47 | 289.57 % |
| 334 | Lite Strategy Inc | 47 | -45.47 % |
| 335 | Karyopharm Therapeutics Inc | 1,234 | 12.3% |
| 336 | Dogwood Therapeutics inc | 46 | -72.06 % |
| 337 | Intercure Ltd | 1,234 | 12.3% |
| 338 | Beyondspring Inc | 1,234 | 12.3% |
| 339 | Werewolf Therapeutics Inc | 1,234 | 12.3% |
| 340 | Pds Biotechnology Corp | 1,234 | 12.3% |
| 341 | Crescent Biopharma Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Dogwood Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Dogwood Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 0.9x | 4.5x | -3.5x |
| Return on Equity | -62.37 % | industry aggregate | -79.62 % |
| Return on Invested Capital | -26.82 % | -2.95 % (avg) | -23.87 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Dogwood Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | 13.08 % | -51.76 % | -24.22 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Dogwood Therapeutics Inc's BCG Growth-Share Matrix
Relative market share (vs Dogwood Therapeutics Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Dogwood Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Dogwood Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 823 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Dogwood Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Dogwood Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Dogwood Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Dogwood Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Dogwood Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 79.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Dogwood Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Dogwood Therapeutics inc | 3.58 | 4.17 | - |
| X4 Pharmaceuticals Inc | 7.70 | 9.26 | 0.13 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Dogwood Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Dogwood Therapeutics inc | Q2 2026 | - | - |
| X4 Pharmaceuticals Inc | Q2 2026 | +21.6 % | - |
| PEERS TOTAL | +21.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Dogwood Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Dogwood Therapeutics inc | Q2 2026 | - | - |
| X4 Pharmaceuticals Inc | Q2 2026 | +396.0 % | - |
Dogwood Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Dogwood Therapeutics inc | - | - | - |
| X4 Pharmaceuticals Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Dogwood Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Dogwood Therapeutics inc | - | - |
| X4 Pharmaceuticals Inc | - | 40.35 |
| PEERS AVERAGE | - | 45.26 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.